These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 767112)

  • 21. Effect of cell-wall skeleton of Mycobacterium bovis BCG on cell-mediated cytotoxicity in tumor-bearing mice.
    Taniyama T; Azuma I; Aladin AA; Yamamura Y
    Gan; 1975 Dec; 66(6):705-9. PubMed ID: 817955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience gained in immunotherapy from the immunopharmacology of BCG leading to a second generation of systemic immunity adjuvants.
    Mathe G
    Comp Immunol Microbiol Infect Dis; 1980; 3(4):407-32. PubMed ID: 6451350
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacologic factors and manipulation of immunity systemic adjuvants in cancer therapy.
    Mathé G; Florentin I; Olsson L; Bruley-Rosset M; Schulz J; Kiger N; Orbach-Arbouys S; Schwarzenberg L; Pouillart P; de Vassal F
    Cancer Treat Rep; 1978 Nov; 62(11):1613-21. PubMed ID: 103616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonspecific immunotherapy of malignant tumors.
    Milas L; Withers HR
    Radiology; 1976 Jan; 118(1):211-8. PubMed ID: 1105663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrophage function in tumor-bearing mice: tumoricidal and chemotactic responses of macrophages activated by infection with Mycobacterium bovis, strain BCG.
    Meltzer MS; Stevenson MM
    J Immunol; 1977 Jun; 118(6):2176-81. PubMed ID: 325142
    [No Abstract]   [Full Text] [Related]  

  • 26. Destruction of tumor cells by BCG-activated alqolar macrophages.
    Zwilling BS; Campolito LB
    J Immunol; 1977 Sep; 119(3):838-41. PubMed ID: 330756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Active immunotherapy in spontaneous leukemia of AkR mice.
    Mathé G; Halle-Pannenko O; Bourut C
    Exp Hematol; 1973; 1(2):110-4. PubMed ID: 4609352
    [No Abstract]   [Full Text] [Related]  

  • 28. Experimental studies of tumor immunotherapy. II. Tumor immunotherapy following tumor extirpation.
    Hayashi S
    Acta Med Okayama; 1976 Jun; 30(3):197-208. PubMed ID: 136871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Water-soluble and lipid-free fraction from BCG with adjuvant and antitumour activity.
    Hiu IJ
    Nat New Biol; 1972 Aug; 238(86):241-2. PubMed ID: 4562114
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunological adjuvants in cancer immunotherapy.
    Baldwin RW
    Dev Biol Stand; 1977 Apr 13-15; 38():3-12. PubMed ID: 344097
    [No Abstract]   [Full Text] [Related]  

  • 31. [Immune manipulation of BCG administered before or after cyclophosphamide for chemo-immunotherapy of L1210 leukemia].
    Mathé G; Halle-Pannenko O; Bourut C
    C R Acad Hebd Seances Acad Sci D; 1975 Apr; 280(13):1623-6. PubMed ID: 811377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunopotentiation with BCG. II. Modulation of the response to sheep red blood cells.
    Miller TE; Mackaness GB; Lagrange PH
    J Natl Cancer Inst; 1973 Nov; 51(5):1669-76. PubMed ID: 4587141
    [No Abstract]   [Full Text] [Related]  

  • 33. On the mode of action of BCG.
    Mitchell MS; Kirkpatrick D; Mokyr MB; Gery I
    Nat New Biol; 1973 Jun; 243(128):216-8. PubMed ID: 4197570
    [No Abstract]   [Full Text] [Related]  

  • 34. Augmentation of specific macrophage-mediated cytotoxicity: correlations with agents which enhance antitumor resistance.
    Schultz RM; Papamatheakis JD; Stylos WA; Chirigos MA
    Cell Immunol; 1976 Aug; 25(2):309-16. PubMed ID: 782731
    [No Abstract]   [Full Text] [Related]  

  • 35. An experimental model for immunotherapy of cancer.
    Zbar B; Ribi E; Rapp HJ
    Natl Cancer Inst Monogr; 1973 Dec; 39():3-9. PubMed ID: 4595326
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunotherapy of guinea pigs with dermal and visceral tumor implants: comparison of living and nonliving BCG.
    Yarkoni E; Peters L; Rapp HJ; Hanna MG; Hunter JT
    Infect Immun; 1979 May; 24(2):565-66. PubMed ID: 378859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer active immunotherapy. Immunoprophylaxis and immunorestoration. An introduction.
    Mathé G
    Recent Results Cancer Res; 1976; 55():1-402. PubMed ID: 1087040
    [No Abstract]   [Full Text] [Related]  

  • 38. [Immunotherapy of cancer with BCG].
    Yamamura Y; Azuma I
    Nihon Rinsho; 1974 Mar; 32(3):542-53. PubMed ID: 4603604
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of Micrococcus, BCG and related polysaccharides in the specific and non-specific immune resistance to murine L1210 leukemia [proceedings].
    Verloes R; Atassi G; Dumont P; Kanarek L
    Arch Int Physiol Biochim; 1978 May; 86(2):466-8. PubMed ID: 81034
    [No Abstract]   [Full Text] [Related]  

  • 40. Detection of complement-dependent antibody to tumor cells in sera of strain-2 guinea pigs cured of their tumors by BCG Treatment.
    Boyle MD; Ohanian SH; Borsos T
    J Natl Cancer Inst; 1976 Mar; 56(3):623-6. PubMed ID: 176400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.